SCHEMBL3029370

SCHEMBL3029370

CCn1nc(-c2ccsc2)c(C(C)=O)c(Nc2cc(F)c(F)c(F)c2)c1=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 1/20 0.54
HTR1A P08908 1/20 0.34
ADRA1D P25100 1/20 0.34
ADRA1A P35348 1/20 0.34
ADRA1B P35368 1/20 0.34
FLT4 P35916 1/20 0.32
MAPK8 P45983 1/20 0.32
MAPK9 P45984 1/20 0.32
CSNK2A1 P68400 1/20 0.32
DYRK1A Q13627 1/20 0.32
AURKB Q96GD4 1/20 0.32
PRKD2 Q9BZL6 1/20 0.32
ADORA3 P0DMS8 3/20 0.32
ADORA2A P29274 3/20 0.32
ADORA1 P30542 3/20 0.32
ADORA2B P29275 1/20 0.32
FPR1 P21462 1/20 0.32
FPR2 P25090 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
NPY2R P49146 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3033419 0.87 PDE4B (0.59) PDE4BHTR1AADRA1DADRA1AADRA1B
SCHEMBL4707463 0.86 PDE4B (0.72) PDE4BHTR1AADRA1DADRA1AADRA1B
SCHEMBL3029481 0.84 PDE4B (0.54) PDE4BSMN1; SMN2
SCHEMBL3029597 0.83 PDE4B (0.58) PDE4BFLT4MAPK8MAPK9CSNK2A1
SCHEMBL1654150 0.83 PDE4B (0.55) PDE4B
SCHEMBL3027254 0.82 PDE4B (0.52) PDE4BADORA3ADORA2AADORA1FPR1
SCHEMBL3037356 0.82 PDE4B (0.52) PDE4BFPR1FPR2SMN1; SMN2
SCHEMBL3022171 0.82 PDE4B (0.58) PDE4BHTR1AADRA1DADRA1AADRA1B
SCHEMBL6187425 0.81 PDE4B (0.71) PDE4BHTR1AADRA1DADRA1AADRA1B
SCHEMBL4708657 0.78 PDE4B (0.73) PDE4BHTR1AADRA1DADRA1AADRA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100204241-A9 NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES LABORATORIOS ALMIRALL, S. A. 2010-08-12 US claimed
US-20090111819-A1 NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES LABORATORIOS ALMIRALL, S. A. 2009-04-30 US claimed
US-7491722-B2 Pyridazin-3(2H)-one derivatives LABORATORIOS ALMIRALL S.A. (ES) 2009-02-17 US claimed
EP-1575926-B1 NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES ALMIRALL LAB (ES) 2008-03-05 EP claimed
US-20060173008-A1 New pyridazin-3(2h)-one derivatives LABORATORIOS ALMIRALL, S.A. (ES) 2006-08-03 US claimed
US-20100204241-A9 NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES LABORATORIOS ALMIRALL, S. A. 2010-08-12 US disclosed
US-20090111819-A1 NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES LABORATORIOS ALMIRALL, S. A. 2009-04-30 US disclosed
US-7491722-B2 Pyridazin-3(2H)-one derivatives LABORATORIOS ALMIRALL S.A. (ES) 2009-02-17 US disclosed
EP-1575926-B1 NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES ALMIRALL LAB (ES) 2008-03-05 EP disclosed
US-20060173008-A1 New pyridazin-3(2h)-one derivatives LABORATORIOS ALMIRALL, S.A. (ES) 2006-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090111819-A1 NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES PDE4A, PDE3A, PDE3B PDE4B 5/4885HTR1A 822/4885ADRA1D 58/4885
US-20060173008-A1 New pyridazin-3(2h)-one derivatives PDE3A, PDE4A, PDE3B PDE4B 4/4885HTR1A 853/4885ADRA1D 73/4885
US-20100204241-A9 NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES PDE4A, PDE3A, PDE3B PDE4B 5/4885HTR1A 822/4885ADRA1D 58/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.